Entero Therapeutics Appoints Richard Paolone as CEO
Portfolio - People | Feb 14, 2025 | EIN
Entero Therapeutics, a clinical-stage biopharmaceutical firm listed on Nasdaq, has appointed Richard Paolone as interim CEO. Based in Toronto, Paolone is a seasoned securities lawyer with vast experience in corporate finance, securities law, and M&A. His role involves advising on strategic initiatives and ensuring compliance with legal and regulatory frameworks, especially in Canada. Prior to his appointment, Paolone has been influential in successful M&A transactions and public offerings. Entero Therapeutics is focusing on non-systemic treatments for GI diseases with products like latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for pancreatic insufficiency correction.
Sectors
- Biopharmaceuticals
- Legal and Corporate Finance
Geography
- United States – Based in Boca Raton, Florida, Entero Therapeutics is a U.S. company, highlighting its geographic operational presence.
- Canada – Richard Paolone's base in Toronto indicates his professional influence and regulatory compliance duties within Canadian markets.
Industry
- Biopharmaceuticals – Entero Therapeutics operates within the biopharmaceutical industry, focusing on developing therapies for gastrointestinal diseases.
- Legal and Corporate Finance – Richard Paolone's background in securities law and corporate finance is crucial for managing M&A and other financial operations within the company.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Entero Therapeutics, Inc. | Target Company | Company | A clinical-stage biopharmaceutical company specializing in GI disease therapies. |
| Richard Paolone | Interim CEO | People | A Toronto-based securities lawyer appointed as interim CEO at Entero Therapeutics. |